Passage Bio Inc (PASG)

Currency in USD
6.3400
-0.7100(-10.07%)
Closed·
After Hours
6.3100-0.0300(-0.47%)
·
PASG Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Earnings results expected tomorrow
Fair Value
Day's Range
6.20007.0300
52 wk Range
5.123926.6000
Key Statistics
Prev. Close
7.05
Open
7.03
Day's Range
6.2-7.03
52 wk Range
5.1239-26.6
Volume
79.8K
Average Volume (3m)
44.9K
1-Year Change
-66.28%
Book Value / Share
15.03
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
PASG Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
120.0000
Upside
+1,792.74%
Members' Sentiments
Bearish
Bullish
ProTips
High shareholder yield

Passage Bio Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Passage Bio Inc Company Profile

Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; and PBKR03, a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and other program for huntington’s disease. It has a strategic research collaboration with the Trustees of the University of Pennsylvania’s Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. The company was incorporated in 2017 and is based in Philadelphia, Pennsylvania.

Compare PASG to Peers and Sector

Metrics to compare
PASG
Peers
Sector
Relationship
P/E Ratio
−0.3x−5.4x−0.5x
PEG Ratio
−0.010.020.00
Price/Book
0.4x3.5x2.6x
Price / LTM Sales
-229.9x3.2x
Upside (Analyst Target)
-167.9%42.0%
Fair Value Upside
Unlock8.1%6.6%Unlock

Analyst Ratings

5 Buy
0 Hold
0 Sell
Ratings:
5 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 120.0000
(+1,792.74% Upside)

Earnings

Latest Release
May 13, 2025
EPS / Forecast
-0.25 / -0.25
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

PASG Income Statement

People Also Watch

15.83
SRPT
+14.21%
0.96
KLTO
-15.04%
0.815
WINT
-11.41%
0.951
GAME
-15.09%
2.19
NMRA
-3.95%

FAQ

What Stock Exchange Does Passage Bio Trade On?

Passage Bio is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Passage Bio?

The stock symbol for Passage Bio is "PASG."

What Is the Passage Bio Market Cap?

As of today, Passage Bio market cap is 19.78M.

What Is Passage Bio's Earnings Per Share (TTM)?

The Passage Bio EPS (TTM) is -20.52.

When Is the Next Passage Bio Earnings Date?

Passage Bio will release its next earnings report on 30 Jul 2025.

From a Technical Analysis Perspective, Is PASG a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Passage Bio Stock Split?

Passage Bio has split 1 times.

How Many Employees Does Passage Bio Have?

Passage Bio has 60 employees.

What is the current trading status of Passage Bio (PASG)?

As of 30 Jul 2025, Passage Bio (PASG) is trading at a price of 6.34, with a previous close of 7.05. The stock has fluctuated within a day range of 6.20 to 7.03, while its 52-week range spans from 5.12 to 26.60.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.